Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting

Published on 2025-06-09 at 16:36

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Keros Therapeutics, Inc.

Keros Therapeutics, Inc. Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept	07-17	CI
Keros Therapeutics, Inc. Provides Update on Global License Agreement with Takeda	07-17	CI
Keros Initiates Dosing in Phase 3 Anemia Trial, Triggering $10 Million Milestone Payment From Takeda	07-17	MT
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000 Value Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 3000 Growth Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2500 Value Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Small Cap Comp Value Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 2500 Growth Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Value Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000E Value Index	06-30	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 2000 Growth Index	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 3000E Growth Index	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 3000E Growth Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 3000 Growth Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 2500 Growth Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell 2000 Growth Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2000 Value Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 2500 Value Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000 Value Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell 3000E Value Benchmark	06-29	CI
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Small Cap Comp Value Benchmark	06-29	CI
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says	06-10	MT

KEROS THERAPEUTICS, INC.

Stock

KROS

US4923271013

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-17 EDT
14.36 ^USD	-0.90%

More quotes

Chart

Duration

Period

KROS: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Employment figures offer some respite for the Bank of England

Results preview: Legrand accelerates

July 17, 2025 at 05:51 am

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 05:24 am

When volatility boosts US banks

July 17, 2025 at 04:42 am

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 03:20 am

The Week's Biggest Mergers Unpacked

July 16, 2025 at 10:12 am

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 09:29 am

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 09:23 am

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 06:16 am

Is Scott Bessent the ideal candidate to succeed Jerome Powell?

July 16, 2025 at 06:06 am

All our articles